Lung Disease
78
5
5
40
Key Insights
Highlights
Success Rate
74% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
17.9%
14 terminated out of 78 trials
74.1%
-12.4% vs benchmark
12%
9 trials in Phase 3/4
25%
10 of 40 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 40 completed trials
Clinical Trials (78)
Study of Lung Proteins in Patients With Pneumonia
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Study of the Disease Process of Lymphangioleiomyomatosis
TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Disease
Point of Care Lung Ultrasound Examination in Patients With Shortness of Breath
Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders
A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease
Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)
NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
Cognitive Screening in Lung Cancer Patients
129 Xenon MRI in Chronic Lung Disease
Spirometry Interpretation Performance of Primary Care Clinicians With/Without AI Software
Comparing Methods for Tracking Health Information at Home After Lung Transplant
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC
Biomarker for Pompe Disease (BioPompe)
Sensing Using Neutrophil Activation Probe on the Intensive Therapy Unit
Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
Regional Lung Imaging Using Hyperpolarized Xenon Gas
Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies
Extending Preservation and Assessment Time of Donor Lungs Using the Toronto EVLP System™ at a Dedicated EVLP Facility